Overview

Venetoclax in Combination With Azacitidine (VEN/AZA) Followed by Donor Lymphocyte Infusion (DLI) for Patients With Very High-Risk Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)

Status:
Not yet recruiting

Trial end date:
2029-07-31

Target enrollment:

Participant gender:

Summary

The purpose of this study is to see the effects of an investigational combination treatment of venetoclax, azacitidine, and donor lymphocyte infusion (DLI) in patients with high-risk AML receiving allogeneic hematopoietic cell transplantation, and to assess if the combination treatment is well tolerated and prevents disease relapse after transplant.

Phase:

Phase 1

Details

Lead Sponsor:

Antonio M Jimenez Jimenez

Collaborator:

AbbVie

Treatments:

Azacitidine
Venetoclax